Measuring brain injury markers (GFAP and UCH-L1) to predict concussion

Measurement of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) to predict symptoms of concussion in high-energy trauma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN18334572

Enrollment

Registered

2025-06-11

Start date

2025-05-25

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Concussion Injury, Occupational Diseases, Poisoning

Interventions

The patient has fallen off a motorcycle and is having a computerised tomography scan of their head to assess injury. They must be conscious and able to provide consent. Blood taken as part of their ro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Competitors in the 2025 Isle of Man TT who are injured during a race or practice session and require a CT scan of their head

Exclusion criteria

Exclusion criteria: Unable to give consent

Design outcomes

Primary

Measure	Time frame
1. Glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) measured using blood test using Abbott i-STAT GFAP/UCH-L1 cartridge point of care testing at time of arrival in the emergency department 2. Screening for concussion using a questionnaire from the Sports Concussion Assessment Tool (version 6) at 2 to 3 weeks following injury by telephone	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Isle of Man

Contacts

Public ContactDavid Frazer

david.frazer@gov.im+44 (0)1624650366

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026